Bulletin
Investor Alert

ALX Oncology Holdings Inc.

NAS: ALXO

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
ALX Oncology Holdings Inc.

After Hours

 --Quotes are delayed by 20 min

Mar 24, 2023, 7:57 p.m.

ALXO
/zigman2/quotes/219511930/composite

$

4.67

Change

+0.01 +0.21%

Volume

Volume 5,783

Quotes are delayed by 20 min

/zigman2/quotes/219511930/composite

Previous close

$ 4.87

$ 4.66

Change

-0.21 -4.31%

Day low

Day high

$4.57

$4.93

Open

52 week low

52 week high

$4.52

$19.85

Open

Company Description

ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. Its objective is to provide clinical therapies for the treatment of myelodysplastic syndromes, acute myeloid leukemia, and a range of solid tumor indicati...

ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. Its objective is to provide clinical therapies for the treatment of myelodysplastic syndromes, acute myeloid leukemia, and a range of solid tumor indications. The company was founded by Corey Goodman, Jaume Pons, and K. Christopher Garcia in March 2015 and is headquartered in South San Francisco, CA.

Valuation

Price to Book Ratio

1.75

Enterprise Value to EBITDA

0.41

Total Debt to Enterprise Value

0.08

Efficiency

Income Per Employee

-2,129,000.00

Liquidity

Current Ratio

9.57

Quick Ratio

9.57

Cash Ratio

9.40

Profitability

Return on Assets

-35.97

Return on Equity

-39.42

Return on Total Capital

-39.53

Return on Invested Capital

-38.41

Capital Structure

Total Debt to Total Equity

5.95

Total Debt to Total Capital

5.62

Total Debt to Total Assets

5.12

Long-Term Debt to Equity

5.56

Long-Term Debt to Total Capital

5.25

Officers and Executives

Name Age Officer Since Title
Dr. Jaume Pons 54 2015 President, Chief Executive Officer & Director
Dr. Michael Chang - 2015 Vice President-Operations
Mr. Peter S. García 58 2020 Chief Financial Officer
Dr. Sophia Randolph 52 2016 Chief Medical Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
12/29/2022 Jaume Pons
President & CEO; Director 		3,232   Disposition at $11.07 per share. 35,778
12/29/2022 Sophia Randolph
Chief Medical Officer; Director 		1,617   Disposition at $11.07 per share. 17,900
12/29/2022 Shelly Pinto
VP, Finance and CAO 		482   Disposition at $11.07 per share. 5,335
12/29/2022 Peter S. García
Chief Financial Officer 		893   Disposition at $11.07 per share. 9,885
12/16/2022 Sophia Randolph
Chief Medical Officer; Director 		25,339   Derivative/Non-derivative trans. at $4.81 per share. 121,880
12/16/2022 Sophia Randolph
Chief Medical Officer; Director 		12,731   Derivative/Non-derivative trans. at $4.08 per share. 51,942
12/16/2022 Sophia Randolph
Chief Medical Officer; Director 		8,404   Derivative/Non-derivative trans. at $1.91 per share. 16,051
08/05/2022 Jaume Pons
President & CEO; Director 		74,000   Award at $0 per share. 0
08/05/2022 Sophia Randolph
Chief Medical Officer; Director 		37,000   Award at $0 per share. 0
08/05/2022 Shelly Pinto
VP, Finance and CAO 		11,000   Award at $0 per share. 0
08/05/2022 Peter S. García
Chief Financial Officer 		29,000   Award at $0 per share. 0
02/07/2022 Peter S. García
Chief Financial Officer 		8,363   Derivative/Non-derivative trans. at $4.81 per share. 40,226
02/07/2022 Peter S. García
Chief Financial Officer 		6,637   Derivative/Non-derivative trans. at $4.08 per share. 27,078
02/03/2022 Jaume Pons
President & CEO; Director 		12,254   Derivative/Non-derivative trans. at $1.91 per share. 23,405
02/03/2022 Jaume Pons
President & CEO; Director 		11,900   Derivative/Non-derivative trans. at $0.99 per share. 11,781
01/28/2022 Shelly Pinto
VP, Finance and CAO 		50,000   Award at $0 per share. 0
12/15/2021 Sophia Randolph
Chief Medical Officer; Director 		11,059   Derivative/Non-derivative trans. at $1.91 per share. 21,122
12/15/2021 Sophia Randolph
Chief Medical Officer; Director 		12,793   Derivative/Non-derivative trans. at $0.99 per share. 12,665
12/13/2021 LSV CAPITAL MANAGEMENT LLC
Director 		60   Disposition at $30.23 per share. 1,813
12/13/2021 LSV CAPITAL MANAGEMENT LLC
Director 		440   Disposition at $30.23 per share. 13,301
12/13/2021 LSV CAPITAL MANAGEMENT LLC
Director 		181   Disposition at $29.6 per share. 5,357
12/13/2021 LSV CAPITAL MANAGEMENT LLC
Director 		1,329   Disposition at $29.6 per share. 39,338
12/13/2021 LSV CAPITAL MANAGEMENT LLC
Director 		299   Disposition at $28.37 per share. 8,482
12/13/2021 LSV CAPITAL MANAGEMENT LLC
Director 		2,196   Disposition at $28.37 per share. 62,300
12/13/2021 LSV CAPITAL MANAGEMENT LLC
Director 		1,296   Disposition at $27.49 per share. 35,627
12/13/2021 LSV CAPITAL MANAGEMENT LLC
Director 		9,509   Disposition at $27.49 per share. 261,402
12/13/2021 LSV CAPITAL MANAGEMENT LLC
Director 		2,339   Disposition at $26.48 per share. 61,936
12/13/2021 LSV CAPITAL MANAGEMENT LLC
Director 		17,169   Disposition at $26.48 per share. 454,635
12/13/2021 LSV CAPITAL MANAGEMENT LLC
Director 		1,627   Disposition at $25.29 per share. 41,146
12/13/2021 LSV CAPITAL MANAGEMENT LLC
Director 		11,945   Disposition at $25.29 per share. 302,089
12/13/2021 LSV CAPITAL MANAGEMENT LLC
Director 		60   Disposition at $30.23 per share. 1,813
12/13/2021 LSV CAPITAL MANAGEMENT LLC
Director 		440   Disposition at $30.23 per share. 13,301
12/13/2021 LSV CAPITAL MANAGEMENT LLC
Director 		181   Disposition at $29.6 per share. 5,357
12/13/2021 LSV CAPITAL MANAGEMENT LLC
Director 		1,329   Disposition at $29.6 per share. 39,338
12/13/2021 LSV CAPITAL MANAGEMENT LLC
Director 		299   Disposition at $28.37 per share. 8,482
12/13/2021 LSV CAPITAL MANAGEMENT LLC
Director 		2,196   Disposition at $28.37 per share. 62,300
12/13/2021 LSV CAPITAL MANAGEMENT LLC
Director 		1,296   Disposition at $27.49 per share. 35,627
12/13/2021 LSV CAPITAL MANAGEMENT LLC
Director 		286,496   Disposition at $27.49 per share. 7,875,775
12/13/2021 LSV CAPITAL MANAGEMENT LLC
Director 		2,339   Disposition at $26.48 per share. 61,936
12/13/2021 LSV CAPITAL MANAGEMENT LLC
Director 		17,169   Disposition at $26.48 per share. 454,635
12/13/2021 LSV CAPITAL MANAGEMENT LLC
Director 		1,627   Disposition at $25.29 per share. 41,146
12/13/2021 LSV CAPITAL MANAGEMENT LLC
Director 		11,945   Disposition at $25.29 per share. 302,089
12/10/2021 LSV CAPITAL MANAGEMENT LLC
Director 		12   Disposition at $32.16 per share. 385
12/10/2021 LSV CAPITAL MANAGEMENT LLC
Director 		88   Disposition at $32.16 per share. 2,830
12/10/2021 LSV CAPITAL MANAGEMENT LLC
Director 		2,172   Disposition at $31.55 per share. 68,526
12/10/2021 LSV CAPITAL MANAGEMENT LLC
Director 		15,942   Disposition at $31.55 per share. 502,970
12/10/2021 LSV CAPITAL MANAGEMENT LLC
Director 		967   Disposition at $30.77 per share. 29,754
12/10/2021 LSV CAPITAL MANAGEMENT LLC
Director 		7,093   Disposition at $30.77 per share. 218,251
12/10/2021 LSV CAPITAL MANAGEMENT LLC
Director 		12   Disposition at $32.16 per share. 385
12/10/2021 LSV CAPITAL MANAGEMENT LLC
Director 		88   Disposition at $32.16 per share. 2,830
12/10/2021 LSV CAPITAL MANAGEMENT LLC
Director 		2,172   Disposition at $31.55 per share. 68,526
12/10/2021 LSV CAPITAL MANAGEMENT LLC
Director 		15,942   Disposition at $31.55 per share. 502,970
12/10/2021 LSV CAPITAL MANAGEMENT LLC
Director 		967   Disposition at $30.77 per share. 29,754
12/10/2021 LSV CAPITAL MANAGEMENT LLC
Director 		7,093   Disposition at $30.77 per share. 218,251
12/09/2021 LSV CAPITAL MANAGEMENT LLC
Director 		1,911   Disposition at $32.73 per share. 62,547
12/09/2021 LSV CAPITAL MANAGEMENT LLC
Director 		14,028   Disposition at $32.73 per share. 459,136
12/09/2021 LSV CAPITAL MANAGEMENT LLC
Director 		5,751   Disposition at $32.06 per share. 184,377
12/09/2021 LSV CAPITAL MANAGEMENT LLC
Director 		42,203   Disposition at $32.06 per share. 1,353,028
12/09/2021 LSV CAPITAL MANAGEMENT LLC
Director 		1,560   Disposition at $31.08 per share. 48,484
12/09/2021 LSV CAPITAL MANAGEMENT LLC
Director 		11,452   Disposition at $31.08 per share. 355,928
12/09/2021 LSV CAPITAL MANAGEMENT LLC
Director 		1,911   Disposition at $32.73 per share. 62,547
12/09/2021 LSV CAPITAL MANAGEMENT LLC
Director 		14,028   Disposition at $32.73 per share. 459,136
12/09/2021 LSV CAPITAL MANAGEMENT LLC
Director 		5,751   Disposition at $32.06 per share. 184,377
12/09/2021 LSV CAPITAL MANAGEMENT LLC
Director 		42,203   Disposition at $32.06 per share. 1,353,028
12/09/2021 LSV CAPITAL MANAGEMENT LLC
Director 		1,560   Disposition at $31.08 per share. 48,484
12/09/2021 LSV CAPITAL MANAGEMENT LLC
Director 		11,452   Disposition at $31.08 per share. 355,928
/news/latest/company/us/alxo

MarketWatch News on ALXO

  2. ALX Oncology stock price target cut to $16 from $35 at Stifel Nicolaus

    7:19 a.m. June 6, 2022

    - Tomi Kilgore

  3. ALX Oncology stock price target cut to $36 from $60 at Stifel Nicolaus

    8:40 a.m. March 1, 2022

    - Tomi Kilgore

  4. ALX Oncology initiated at buy with $106 target price at Stifel

    7:04 a.m. Sept. 30, 2021

    - Tonya Garcia

  5. ALX Oncology started at buy with $96 stock price target at UBS

    8:51 a.m. April 6, 2021

    - Tomi Kilgore

  6. Biotech stocks are a buy — especially these 18 picks

    2:02 p.m. March 13, 2021

    - Michael Brush

  7. ALX Oncology sets IPO terms, to raise up to $136 million

    8:29 a.m. July 13, 2020

    - Tomi Kilgore

/news/nonmarketwatch/company/us/alxo

Other News on ALXO

  1. These Biotechs Were Told Their SVB Funds Were Available. It Wasn’t That Simple.

    12:38 p.m. March 15, 2023

    - The Wall Street Journal Interactive Edition

  2. 10-Q: ALX ONCOLOGY HOLDINGS INC

    5:26 p.m. Nov. 8, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  4. ALX Oncology (ALXO) Investor Presentation - Slideshow

    12:36 p.m. Sept. 30, 2022

    - Seeking Alpha

  5. Monster Moves Among Russell 3,000 Stocks

    2:40 a.m. Aug. 9, 2022

    - Seeking Alpha

  6. 10-Q: ALX ONCOLOGY HOLDINGS INC

    4:38 p.m. Aug. 8, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  11. ALX Oncology files for $450 mixed shelf offering

    5:32 p.m. March 25, 2022

    - Seeking Alpha

  13. ALX Oncology Is Turning Into An Also-Ran In Anti-CD47

    8:27 a.m. Feb. 15, 2022

    - Seeking Alpha

  18. New Strong Sell Stocks for January 19th

    7:23 a.m. Jan. 19, 2022

    - Zacks.com

  19. ALX Oncology plunges as director sells shares worth $75M

    3:31 p.m. Dec. 16, 2021

    - Seeking Alpha

  21. Loading more headlines...

At a Glance

ALX Oncology Holdings, Inc.

323 Allerton Avenue

South San Francisco, California 94080

Phone

1 6504667125

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2023

View SEC Filings

Revenue

N/A

Net Income

$-123.48M

Employees

58.00

Annual Report for ALXO

/news/pressrelease/company/us/alxo

Press Releases on ALXO

  8. ALX Oncology Appoints Scott Garland to its Board of Directors

    8:00 a.m. Nov. 29, 2022

    - GlobeNewswire

  21. Loading more headlines...
Link to MarketWatch's Slice.